Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention

GlobeNewswire 5 hours ago

Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference

GlobeNewswire 2 days ago

First Wave BioPharma Changes Name to Entero Therapeutics

GlobeNewswire 6 days ago

First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market

GlobeNewswire 12 days ago

First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month

GlobeNewswire 13 days ago

First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients

GlobeNewswire April 24, 2024

First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase

GlobeNewswire April 17, 2024

First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference

GlobeNewswire April 15, 2024

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

GlobeNewswire March 18, 2024

First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline

GlobeNewswire March 14, 2024

First Wave BioPharma to Participate In 'Fireside Chat' at the 36th Annual Roth Conference

GlobeNewswire March 5, 2024

First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering

GlobeNewswire March 4, 2024

First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024

GlobeNewswire February 13, 2024

First Wave BioPharma to Present at the DealFlow MicroCap Conference

GlobeNewswire January 23, 2024

First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico

GlobeNewswire January 17, 2024

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

GlobeNewswire January 4, 2024

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

GlobeNewswire December 27, 2023

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

GlobeNewswire December 27, 2023

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

GlobeNewswire December 18, 2023

First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

GlobeNewswire December 14, 2023